Another monoclonal anti-IL1RAP antibody (Nadunolimab, CAN04, Cantargia AB) that mainly blocks IL-1 signalling and has enhanced antibody-dependent cellular cytotoxicity (ADCC)-inducing properties (afucosylated) is currently undergoing clinical trials for efficacy against non–small-cell lung cancer, triple negative breast cancer, and pancreatic cancer in combination with chemotherapy (NCT05116891, NCT04990037, NCT03267316, NCT05181462) or pembrolizumab (anti-PD1; NCT04452214). Here, IL1A is linked to lung cancer.